Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 53, Issue 7

Issues

Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children

Sophia Sakka
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tania Siahanidou
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Chronis Voyatzis / Panagiota Pervanidou
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christina Kaminioti / Natalia Lazopoulou
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christina Kanaka-Gantenbein
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ George P. Chrousos
  • Division of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, Athens University Medical School, Athens, Greece
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ioannis Papassotiriou
Published Online: 2015-01-10 | DOI: https://doi.org/10.1515/cclm-2014-1081

Abstract

Background: Obesity and cardiovascular disease (CVD) often co-exist, but the pathophysiologic mechanisms that link the two are not fully understood. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is involved in the modification of lipids within atheromatous plaques. Recently, circulating Lp-PLA2 was found to be predictive of thromboembolic episodes in adults, independently of a variety of other potential risk factors, including markers of inflammation, renal function, and hemodynamic stress. However, the function of this lipase and its importance as a biomarker in childhood obesity is much less studied. The aim of the study was to study Lp-PLA2, a non-traditional risk factor of CVD, in obese children.

Methods: Sixty-seven lean [39 boys and 28 girls, mean body mass index (BMI) z-score –0.2±0.8] and 66 obese (32 boys and 34 girls, mean BMI z-score 4.4±1.2) age-matched (p=0.251) children, aged 6–12 years, were studied. BMI z-score was calculated based on the Greek BMI growth curves, and children were categorized as obese according to the Cole criteria. All children underwent physical examination and a fasting morning blood sample was obtained for glucose, insulin, lipid profile, and Lp-PLA2 assessment. Plasma concentrations of Lp-PLA2 were determined by a commercially available Lp-PLA2 enzyme-linked immunosorbent assay kit (PLAC Test), while other measurements were performed using standard methods.

Results: Plasma Lp-PLA2 levels were significantly higher in obese children (322.5±77.8 ng/mL) compared with normal-weight ones (278.0±64.4 ng/mL, p<0.001). Lp-PLA2 concentrations were significantly correlated with the BMI z-score (p=0.004). Receiver operating characteristic analysis on Lp-PLA2 values resulted in significant areas under the curve (AUC) for distinguishing between obese and normal-weight groups of children (AUC, 0.726; p<0.001).

Conclusions: We found significantly higher Lp-PLA2 levels in obese children than lean controls. Interestingly, they all had levels >200 ng/mL, which are considered to correlate with atherosclerosis and a high thromboembolic risk in adults. The positive correlation of Lp-PLA2 with BMI suggests that Lp-PLA2 might be the link between obesity and increased cardiovascular risk, which can be elevated even at a very young age. Measurement of Lp-PLA2 in plasma could therefore represent a further biomarker for assessing increased CVD risk in obese children and adolescents.

Keywords: biomarkers; BMI; cardiovascular risk; children; lipids; lipoprotein-associated phospholipase A2 (Lp-PLA2); obesity

References

  • 1.

    Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008;37:603–21.CrossrefPubMedGoogle Scholar

  • 2.

    Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327–38.Web of ScienceGoogle Scholar

  • 3.

    Macphee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999;338:479–87.Google Scholar

  • 4.

    Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007;115:2715–21.Google Scholar

  • 5.

    Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005;2:529–35.PubMedCrossrefGoogle Scholar

  • 6.

    Packard CJ, O’Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148–55.Google Scholar

  • 7.

    Ballantyne C, Hoogeveen R, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004;109:837–42.CrossrefPubMedGoogle Scholar

  • 8.

    Koenig W, Meisinger C, Trischler G, Khuseyinova N, Lowel H. Lipoprotein-associated phospholipase A2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation 2004;110:1903–8.Google Scholar

  • 9.

    Oei HH, Van der Meer IM, Hofman A, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005;111:570–5.CrossrefPubMedGoogle Scholar

  • 10.

    Katan M, Moon YP, Paik MC, Wolfert RL, Sacco RL, Elkind MS. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One 2014;9:e83393.Web of SciencePubMedGoogle Scholar

  • 11.

    Fortunato J, Bláha V, Bis J, St’ásek J, Andrýs C, Vojáček J, et al. Lipoprotein-associated phospholipase A2 mass level is increased in elderly subjects with type 2 diabetes mellitus. J Diabetes Res 2014;2014:278063.Web of ScienceGoogle Scholar

  • 12.

    Nelson TL, Biggs ML, Kizer JR, Cushman M, Hokanson JE, Furberg CD, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study. J Clin Endocrinol Metab 2012;97:1695–701.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 13.

    Gong HP, Du YM, Zhong LN, Dong ZQ, Wang X, Mao YJ, et al. Plasmalipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis 2011;10:13.Web of ScienceCrossrefGoogle Scholar

  • 14.

    Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged non diabetic subjects. Arterioscler Thromb Vasc Biol 2007;27:1411–6.Web of ScienceCrossrefGoogle Scholar

  • 15.

    Mansoub S, Chan MK, Adeli K. Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome. Clin Biochem 2006;39:569–87.CrossrefPubMedGoogle Scholar

  • 16.

    da Silva IT, Timm Ade S, Damasceno NR. Influence of obesity and cardiometabolic markers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis 2013;12:19.Web of ScienceGoogle Scholar

  • 17.

    Nagel G, Rapp K, Wabitsch M, Büchele G, Kroke A, Zöllner I, et al. Prevalence and cluster of cardiometabolic biomarkers in overweight and obese schoolchildren: results from a large survey in southwest Germany. Clin Chem 2008;54:317–25.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 18.

    Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i–xii,1–253.Google Scholar

  • 19.

    Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J 2000;320:1–6.Google Scholar

  • 20.

    Chiotis D, Krikos X, Tsiftis G, Hatzisymeon M, Maniati-Christidi M, Dacou-Voutetaki A. Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0-18 years living in the Athens area. Ann Clin Pediatr Unive Atheniensis 2004;51:139–54.Google Scholar

  • 21.

    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555–76.PubMedGoogle Scholar

  • 22.

    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.PubMedCrossrefGoogle Scholar

  • 23.

    Hirschler V, Meroño T, Maccallini G, Gomez Rosso L, Aranda C, Brites F. Association of lipoprotein-associated phospholipase A2 activity with components of the metabolic syndrome in apparently healthy boys. Cardiovasc Hematol Agents Med Chem 2011;9:78–83.Google Scholar

  • 24.

    Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008;101:51F–7F.Web of ScienceCrossrefGoogle Scholar

  • 25.

    Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, Tsimikas S. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol 2011;5:50–6.Web of ScienceCrossrefPubMedGoogle Scholar

  • 26.

    Lenzini L, Antezza K, Caroccia B, Wolfert RL, Szczech R, Cesari M, et al. A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity. Atherosclerosis 2009;205:181–5.Google Scholar

  • 27.

    Maiolino G, Lenzini L, Pedon L, Cesari M, Seccia TM, Frigo AC, et al. Lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease. J Cardiovasc Med (Hagerstown) 2015;16:19–36.Web of ScienceGoogle Scholar

  • 28.

    Okada T, Miyashita M, Kuromori Y, Iwata F, Harada K, Hattori H. Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler Thromb Vasc Biol 2006;26:e40–1.PubMedCrossrefGoogle Scholar

  • 29.

    Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. Antiinflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995;374:549–53.Google Scholar

  • 30.

    Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000;150:413–9.Google Scholar

  • 31.

    Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536–44.Google Scholar

  • 32.

    Motykova E, Zlatohlavek L, Prusikova M, Lanska V, Ceska R, Vasickova L, et al. Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children. Neuro Endocrinol Lett 2011;32:55–9.PubMedGoogle Scholar

  • 33.

    Verona J, Gilligan LE, Giménez C, Verona MF, Lombardo SM, Baenz A, et al. Physical activity and cardiometabolic risk in male children and adolescents: the Balcarce study. Life Sci 2013;93:64–8.CrossrefPubMedGoogle Scholar

  • 34.

    Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059–66.Web of ScienceGoogle Scholar

  • 35.

    Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172–82.Google Scholar

About the article

Corresponding author: Dr Ioannis Papassotiriou, Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hospital Athens 11527, Greece, Phone/Fax: +30-213-2013171, E-mail: ;


Received: 2014-11-04

Accepted: 2014-12-04

Published Online: 2015-01-10

Published in Print: 2015-06-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 53, Issue 7, Pages 1119–1125, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2014-1081.

Export Citation

©2015 by De Gruyter. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Xueling Lu, Xijin Xu, Yu Zhang, Yuling Zhang, Chenyang Wang, and Xia Huo
Environmental Pollution, 2018, Volume 234, Page 601
[2]
Julia Seyfarth, Thomas Reinehr, Annika Hoyer, Christina Reinauer, Christina Bächle, Beate Karges, Ertan Mayatepek, Michael Roden, Sabine E. Hofer, Susanna Wiegand, Joachim Woelfle, Wieland Kiess, Joachim Rosenbauer, Reinhard W. Holl, and Thomas Meissner
Journal of Inherited Metabolic Disease, 2017
[3]
Carolin Schliefsteiner, Birgit Hirschmugl, Susanne Kopp, Sanja Curcic, Eva Maria Bernhart, Gunther Marsche, Uwe Lang, Gernot Desoye, and Christian Wadsack
Scientific Reports, 2017, Volume 7, Number 1
[4]
Daniel Mønsted Shabanzadeh, Tea Skaaby, Lars Tue Sørensen, Jesper Eugen-Olsen, and Torben Jørgensen
Scandinavian Journal of Gastroenterology, 2017, Page 1
[5]
Minjoo Kim, Minkyung Kim, Hye Jin Yoo, Hye Young Jang, Sang-Hyun Lee, Jong Ho Lee, and Alberto G Passi
PLOS ONE, 2017, Volume 12, Number 3, Page e0173611
[6]
Belkız Öngen, Sema Kalkan Uçar, Ertürk Levent, Elif Azarsız, Turan Koloğlu, Mahmut Çoker, Eser Sözmen, and Ferhan G Sağın
Annals of Clinical Biochemistry, 2016, Page 000456321667133

Comments (0)

Please log in or register to comment.
Log in